Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cinitapride - Almirall-Prodesfarma

Drug Profile

Cinitapride - Almirall-Prodesfarma

Alternative Names: Blaston; Cidine; Cinigest; Cinitapride acid tartrate; Cinitapride hydrogen tartrate; LAS 17177; Pemix

Latest Information Update: 15 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A.; Eisai Co Ltd; Lacer
  • Class Benzamides; Gastrokinetics
  • Mechanism of Action Serotonin 2 receptor agonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyspepsia; Gastro-oesophageal reflux; Gastrointestinal motility disorders

Most Recent Events

  • 14 Mar 2018 Launched for Dyspepsia in China (PO)
  • 01 Feb 2015 Registered for Dyspepsia in China (PO) (Eisai pipeline, May 2015)
  • 03 Feb 2014 Approval is still being sought for Dyspepsia in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top